Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000460221 | SCV000544953 | pathogenic | Marfan syndrome | 2016-06-13 | criteria provided, single submitter | clinical testing | This sequence change deletes 1 nucleotide from exon 9 of the FBN1 mRNA (c.978delC), causing a frameshift at codon 327. This creates a premature translational stop signal (p.Arg327Aspfs*3) and is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, truncating variants in FBN1 are known to be pathogenic (PMID: 17657824, 19293843). For these reasons, this variant has been classified as Pathogenic. |
Labcorp Genetics |
RCV001389424 | SCV001590785 | pathogenic | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2016-06-13 | criteria provided, single submitter | clinical testing | This sequence change deletes 1 nucleotide from exon 9 of the FBN1 mRNA (c.978delC), causing a frameshift at codon 327. This creates a premature translational stop signal (p.Arg327Aspfs*3) and is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, truncating variants in FBN1 are known to be pathogenic (PMID: 17657824, 19293843). For these reasons, this variant has been classified as Pathogenic. |
Mayo Clinic Laboratories, |
RCV001843950 | SCV002103263 | pathogenic | not provided | 2021-12-22 | criteria provided, single submitter | clinical testing | PP4, PM2, PVS1 |